OGN

시간 외 거래: 11.17 0.05 +0.45%

오가논 & Co (OGN)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 배당 이력

Relative Volume:

오가논 & Co Stock (OGN) Company Profile

Healthcare (1151)

551-430-6000

30 HUDSON STREET, JERSEY CITY

최신 SEC 제출 서류

OGN's Discussions on Twitter

OGN을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
OGN Organon Co	11.12	2.91B	6.41B	1.30B	646.00M	5.04
LLY Lilly Eli Co	839.96	677.40B	45.04B	10.59B	414.30M	11.71
JNJ Johnson Johnson	157.47	371.98B	89.33B	21.81B	18.06B	8.99
ABBV Abbvie Inc	172.99	316.82B	56.33B	4.28B	17.83B	2.40
NVO Novo Nordisk Adr	58.08	293.24B	42.09B	14.65B	10.11B	3.2833
NVS Novartis Ag Adr	110.86	216.19B	51.72B	11.94B	13.81B	5.88

오가논 & Co Stock (OGN) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-09-06	다운그레이드	JP Morgan	Neutral → Underweight
2023-11-03	다운그레이드	Goldman	Buy → Neutral
2023-09-21	개시	Barclays	Overweight
2023-03-16	개시	Raymond James	Outperform
2022-10-14	다운그레이드	BofA Securities	Neutral → Underperform
2022-09-06	업그레이드	Piper Sandler	Neutral → Overweight
2022-08-05	다운그레이드	BofA Securities	Buy → Neutral
2022-04-27	개시	Goldman	Buy
2022-04-06	재개	Morgan Stanley	Equal-Weight
2021-10-07	개시	Piper Sandler	Neutral
2021-09-01	개시	BofA Securities	Buy
2021-07-22	개시	Citigroup	Buy
2021-06-15	개시	JP Morgan	Neutral
2021-06-11	개시	Morgan Stanley	Equal-Weight
2021-06-10	개시	Evercore ISI	Outperform

오가논 & Co 주식(OGN)의 최신 뉴스

오가논 & Co (OGN) 재무 분석

오가논 & Co (OGN)

오가논 & Co Stock (OGN) Company Profile

OGN을(를) 다른 주식과 비교

오가논 & Co Stock (OGN) Upgrades & Downgrades

오가논 & Co 주식(OGN)의 최신 뉴스

(OGN) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Ganirelix Market Is Booming Worldwide 2025-2032 | Organon & Co.,Merck & Co., Inc.,Ferring Pharmaceuticals - openPR.com

Organon stock hits 52-week low at $10.92 amid market challenges By Investing.com - Investing.com South Africa

Organon stock hits 52-week low at $10.92 amid market challenges - Investing.com Australia

Organon expands board with new director from Takeda - Investing.com

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Bluefield Daily Telegraph

Takeda President Ramona Sequeira Joins Organon Board: Major Win for Women's Health Giant - Stock Titan

Organon & CoExpects $6 Million Milestone Expense In Q1 2025 - MarketScreener

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - Bluefield Daily Telegraph

Organon Earnings Alert: Q1 2025 Results Coming May 1 with $6M Milestone Expenses - Stock Titan

Organon (OGN) Laps the Stock Market: Here's Why - Yahoo Finance

EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - MarketScreener

Organon's NDURVA Cream Gets Health Canada Approval for Plaque Psoriasis Treatment - MarketScreener

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - 뉴스와이어

Organon's Ba2 CFR affirmed by Moody's, outlook revised to negative - Investing.com Australia

Organon’s Ba2 CFR affirmed by Moody’s, outlook revised to negative - Investing.com Canada

Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength? - Nasdaq

Organon (OGN) Sees Flat Revenue, Downgraded Full-Year Outlook - GuruFocus

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance

Organon Enters Oversold Territory - Nasdaq

Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance

Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune

Organon stock hits 52-week low at $13.84 amid market challenges - Investing.com Canada

Organon stock hits 52-week low at $13.84 amid market challenges By Investing.com - Investing.com South Africa

Organon (OGN) Stock Moves -1.83%: What You Should Know - Yahoo Finance

Why Organon (OGN) Could Beat Earnings Estimates Again - Yahoo Finance

Organon acquires Actemra biosimilar’s US rights from Biogen - Pharmaceutical Technology

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition - insights.citeline.com

Organon acquires US rights to arthritis biosimilar TOFIDENCE By Investing.com - Investing.com South Africa

Organon Expands Biosimilar Portfolio With Tofidence Acquisition - Managed Healthcare Executive

Organon Acquires TOFIDENCE - citybiz

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance

Organon Acquires Tofidence for Intravenous Infusion in US - MarketScreener

Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra - Seeking Alpha

Organon acquires rights for Tofidence from Biogen - TipRanks

Organon acquires US rights to arthritis biosimilar TOFIDENCE - Investing.com

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. - Bluefield Daily Telegraph

Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal - Stock Titan

Natixis Advisors LLC Decreases Stock Holdings in Organon & Co. (NYSE:OGN) - MarketBeat

Organon (OGN) Stock Moves -0.34%: What You Should Know - Yahoo Finance

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug - MarketScreener

European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11 - MarketScreener

Organon, Shanghai Henlius Biotech: EMA validates MAA for HLX11 - TipRanks

Major Win: Organon's Breast Cancer Drug Gets Critical EMA Validation After Trial Success - Stock Titan

Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance

Organon & Co. (OGN): A Deep Value Play with a 35.96% Upside Potential and an Attractive 7.61% Dividend Yield - DirectorsTalk Interviews

Connor Clark & Lunn Investment Management Ltd. Purchases New Position in Organon & Co. (NYSE:OGN) - MarketBeat

Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price - simplywall.st

오가논 & Co (OGN) 재무 분석

매출

순이익

현금흐름

주당 순 이익

OGN과 유사한 종목